Equities analysts expect Bruker Co. (NASDAQ:BRKR) to post sales of $418.40 million for the current quarter, according to Zacks. Seven analysts have issued estimates for Bruker’s earnings, with the lowest sales estimate coming in at $403.40 million and the highest estimate coming in at $433.40 million. Bruker reported sales of $384.90 million during the same quarter last year, which indicates a positive year-over-year growth rate of 8.7%. The company is expected to issue its next quarterly earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Bruker will report full-year sales of $418.40 million for the current year, with estimates ranging from $1.86 billion to $1.89 billion. For the next fiscal year, analysts forecast that the firm will post sales of $1.95 billion per share, with estimates ranging from $1.91 billion to $1.98 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Bruker.
Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 8th. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.02. Bruker had a return on equity of 26.58% and a net margin of 4.45%. The business had revenue of $530.50 million during the quarter, compared to analysts’ expectations of $506.74 million. During the same period in the prior year, the business earned $0.46 EPS. Bruker’s revenue for the quarter was up 12.8% compared to the same quarter last year.
BRKR has been the subject of a number of recent research reports. Leerink Swann upped their price target on Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a research report on Friday, February 9th. Morgan Stanley reduced their price target on Bruker from $35.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. BidaskClub downgraded Bruker from a “buy” rating to a “hold” rating in a research report on Saturday, February 10th. BTIG Research initiated coverage on Bruker in a research report on Friday, January 5th. They set a “buy” rating and a $42.00 price target for the company. Finally, Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $32.62.
Bruker (BRKR) traded down $0.20 during midday trading on Tuesday, reaching $32.10. The company had a trading volume of 262,895 shares, compared to its average volume of 597,693. Bruker has a twelve month low of $21.83 and a twelve month high of $36.53. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65. The company has a market cap of $4,993.57, a PE ratio of 65.51, a price-to-earnings-growth ratio of 2.13 and a beta of 1.05.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its holdings in shares of Bruker by 346.7% in the 4th quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock valued at $128,000 after buying an additional 2,878 shares during the last quarter. Zions Bancorporation acquired a new stake in shares of Bruker in the 3rd quarter valued at approximately $119,000. SG Americas Securities LLC acquired a new stake in shares of Bruker in the 4th quarter valued at approximately $145,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Bruker by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after buying an additional 331 shares during the last quarter. Finally, Wolverine Trading LLC acquired a new stake in shares of Bruker in the 4th quarter valued at approximately $201,000. 64.78% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “$418.40 Million in Sales Expected for Bruker Co. (BRKR) This Quarter” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/18/418-40-million-in-sales-expected-for-bruker-co-brkr-this-quarter-2.html.
Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.
Get a free copy of the Zacks research report on Bruker (BRKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.